Journal
ACS CHEMICAL BIOLOGY
Volume 13, Issue 8, Pages 2048-2057Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acschembio.8b00251
Keywords
-
Categories
Funding
- National Institutes of Health [R21NS096531, T32NS048039]
- UAB mitochondrial medicine laboratory
- University of Alabama at Birmingham
- Department of Cell, Developmental and Integrative Biology
- Comprehensive Cancer Center
- Civitan International Research Center for Glial Biology in Medicine
- Center for Free Radical Biology
- Neuro-Oncology Brain SPORE
- [P30 G050886-01]
- [R01NS081366]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS048039, R21NS096531, R01NS081366] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE ON AGING [P30AG050886] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Tumor heterogeneity has hampered the development of novel effective therapeutic options for aggressive cancers, including the deadly primary adult brain tumor glioblastoma (GBM). Intratumoral heterogeneity is partially attributed to the tumor initiating cell (TIC) subset that contains highly tumorigenic, stem-like cells. TICs display metabolic plasticity but can have a reliance on aerobic glycolysis. Elevated expression of GLUT1 and GLUT3 is present in many cancer types, with GLUT3 being preferentially expressed in brain TICs (BTICs) to increase survival in low nutrient tumor microenvironments, leading to tumor maintenance. Through structure-based virtual screening (SBVS), we identified potential novel GLUT inhibitors. The screening of 13 compounds identified two that preferentially inhibit the growth of GBM cells with minimal toxicity to non-neoplastic astrocytes and neurons. These compounds, SRI-37683 and SRI-37684, also inhibit glucose uptake and decrease the glycolytic capacity and glycolytic reserve capacity of GBM patient-derived xenograft (PDX) cells in glycolytic stress test assays. Our results suggest a potential new therapeutic avenue to target metabolic reprogramming for the treatment of GBM, as well as other tumor types, and the identified novel inhibitors provide an excellent starting point for further lead development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available